281 related articles for article (PubMed ID: 33079176)
1. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
Das M; Dalal A; Laxmeshwar C; Ravi S; Mamnoon F; Meneguim AC; Paryani R; Mathur T; Singh P; Mansoor H; Kalon S; Hossain FN; Lachenal N; Coutisson S; Ferlazzo G; Isaakidis P
Clin Infect Dis; 2021 Nov; 73(9):e3496-e3504. PubMed ID: 33079176
[TBL] [Abstract][Full Text] [Related]
2. New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India.
Das M; Mamnoon F; Mansoor H; Meneguim AC; Singh P; Shah I; Ravi S; Kalon S; Hossain FN; Ferlazzo G; Isaakidis P; Furin J; Acharya S; Thakur HP
Int J Tuberc Lung Dis; 2020 Dec; 24(12):1265-1271. PubMed ID: 33317670
[No Abstract] [Full Text] [Related]
3. Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
Sarin R; Vohra V; Singla N; Singla R; Puri MM; Munjal SK; Khalid UK; Myneedu VP; Verma A; Mathuria KK
Indian J Tuberc; 2019 Jan; 66(1):184-188. PubMed ID: 30878066
[TBL] [Abstract][Full Text] [Related]
4. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
[TBL] [Abstract][Full Text] [Related]
5. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Huerga H; Khan U; Bastard M; Mitnick CD; Lachenal N; Khan PY; Seung KJ; Melikyan N; Ahmed S; Rich ML; Varaine F; Osso E; Rashitov M; Salahuddin N; Salia G; Sánchez E; Serobyan A; Rafi Siddiqui M; Grium Tefera D; Vetushko D; Yeghiazaryan L; Holtzman D; Islam S; Kumsa A; Jacques Leblanc G; Leonovich O; Mamsa S; Manzur-Ul-Alam M; Myint Z; Padayachee S; Franke MF; Hewison C
Clin Infect Dis; 2022 Oct; 75(8):1307-1314. PubMed ID: 35243494
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.
Dhakulkar S; Das M; Sutar N; Oswal V; Shah D; Ravi S; Vengurlekar D; Chavan V; Rebello L; Meneguim AC; Iyer A; Mansoor H; Kalon S; Acharya S; Ferlazzo G; Isaakidis P; Thakur HP
PLoS One; 2021; 16(2):e0246639. PubMed ID: 33600431
[TBL] [Abstract][Full Text] [Related]
7. Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini.
Vambe D; Kay AW; Furin J; Howard AA; Dlamini T; Dlamini N; Shabangu A; Hassen F; Masuku S; Maha O; Wawa C; Mafukidze A; Altaye K; Sikhondze W; Gwitima T; Keus K; Simelane T; Kerschberger B
Int J Tuberc Lung Dis; 2020 Oct; 24(10):1095-1102. PubMed ID: 33126945
[No Abstract] [Full Text] [Related]
8. Feasibility of a "Salvage Regimen" Using Home-based Intravenous Meropenem Therapy With a Delamanid/Bedaquilline Containing Regimen in the Management of MDR/XDR Pediatric Tuberculosis.
Shah I; Antony S; Jaiswal A; Bodhanwala M; Shah D; Tipre P; Salve J; Parmar M; Sachdeva KS
Pediatr Infect Dis J; 2022 May; 41(5):401-404. PubMed ID: 35153288
[TBL] [Abstract][Full Text] [Related]
9. Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India.
Mongia H; Mamnoon F; Silsarma A; Mahajan R; Dalal A; Galindo MA; Iyer A; Singh P; Mansoor H; Das M; Morales M; Spencer H; Isaakidis P
J Clin Tuberc Other Mycobact Dis; 2024 May; 35():100433. PubMed ID: 38617837
[TBL] [Abstract][Full Text] [Related]
10. Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid.
Lee HH; Jo KW; Yim JJ; Jeon D; Kang H; Shim TS
Int J Infect Dis; 2020 Sep; 98():478-485. PubMed ID: 32640367
[TBL] [Abstract][Full Text] [Related]
11. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.
Kempker RR; Mikiashvili L; Zhao Y; Benkeser D; Barbakadze K; Bablishvili N; Avaliani Z; Peloquin CA; Blumberg HM; Kipiani M
Clin Infect Dis; 2020 Dec; 71(9):2336-2344. PubMed ID: 31712809
[TBL] [Abstract][Full Text] [Related]
14. Strengthened capacity of India´s bedaquiline Conditional Access Programme for introducing new drugs and regimens.
Sachdeva KS; Arora N; Solanki R; Singla R; Sarin R; Bhatnagar A; Khanna A; Atahavale A; Shridhar R; Barua SR; Parmar M; Farooq SI; Ramachandran R; Alavadi U; Swamickan R; Tonsing J; Patel Y; Singla N
Int J Tuberc Lung Dis; 2020 Oct; 24(10):1067-1072. PubMed ID: 33126941
[No Abstract] [Full Text] [Related]
15. Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19.
Solodovnikova V; Kumar AMV; Hurevich H; Sereda Y; Auchynka V; Katovich D; Klimuk D; Skrahin A; Setkina S; Charnysh I; Yedilbayev A; Skrahina A
Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470080
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of bedaquiline and delamanid in the treatment of drug-resistant tuberculosis in adults: A systematic review and meta-analysis.
Ahmed SH; Haider H; Moeed A; Mahmood A; Shivani N; Shuja SH; Hayat J; Jamil B; Fatima R
Indian J Tuberc; 2024 Jan; 71(1):79-88. PubMed ID: 38296395
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
18. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
Han X; Chen X; Sha W; Zhang X; Qiu L; Wang J; Wu G; Yao L; Lv Y; Zhang X; Zhou J; Tang S; Chu N
Int J Tuberc Lung Dis; 2020 Aug; 24(8):789-794. PubMed ID: 32912383
[No Abstract] [Full Text] [Related]
19. Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis.
Cox V; Brigden G; Crespo RH; Lessem E; Lynch S; Rich ML; Waning B; Furin J
Int J Tuberc Lung Dis; 2018 Apr; 22(4):407-412. PubMed ID: 29562988
[TBL] [Abstract][Full Text] [Related]
20. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]